Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kevin Kalinsky

Showing results (61-70 of 151) with videos related to

Pageof 16
Sort By:
Breast Cancer Research and Treatment|April 21, 2018
A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammationJoyce O'Shaughnessy, Angela DeMichele, Cynthia X Ma, et al.
Cardiovascular and Interventional Radiology|August 25, 2022
Study Protocol: Efficacy and Safety of Radioembolization (REM) as an Early Modality (EM) Therapy for Metastatic Breast Cancer (BR) to the Liver with Y90 (REMEMBR Y90)Richard Wu, Keerthi Gogineni, Jane Meisel, et al.
Clinical Breast Cancer|March 7, 2020
A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast CancerReshma Mahtani, Frankie-Ann Holmes, Sunil Badve, et al.
Journal of the Academy of Nutrition and Dietetics|January 13, 2015
¡Cocinar Para Su Salud!: Randomized Controlled Trial of a Culturally Based Dietary Intervention among Hispanic Breast Cancer SurvivorsHeather Greenlee, Ann Ogden Gaffney, A Corina Aycinena, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2021
Changes in Diffuse Optical Tomography Images During Early Stages of Neoadjuvant Chemotherapy Correlate with Tumor Response in Different Breast Cancer SubtypesMirella L Altoe, Kevin Kalinsky, Alessandro Marone, et al.
NPJ Breast Cancer|November 13, 2025
Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010-2021Alexandra Thomas, Anthony Rhoads, Erica L Mayer, et al.
Breast Cancer Research : BCR|February 1, 2021
Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomographyMirella L Altoe, Kevin Kalinsky, Alessandro Marone, et al.
Cancer Investigation|September 26, 2014
Increased expression of tumor proliferation genes in Hispanic women with early-stage breast cancerKevin Kalinsky, Emerson A Lim, Eleni Andreopoulou, et al.
Breast Cancer Research and Treatment|June 13, 2024
Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practiceManali A Bhave, Julia C F Quintanilha, Hanna Tukachinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2025
Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast CancerMaxwell R Lloyd, Caroline M Weipert, Azka Ali, et al.
Pageof 16

Showing results (61-70 of 151) with videos related to

Sort By:
Pageof 16
Breast Cancer Research and Treatment|April 21, 2018
A randomized, double-blind, phase 2 study of ruxolitinib or placebo in combination with capecitabine in patients with advanced HER2-negative breast cancer and elevated C-reactive protein, a marker of systemic inflammationJoyce O'Shaughnessy, Angela DeMichele, Cynthia X Ma, et al.
Cardiovascular and Interventional Radiology|August 25, 2022
Study Protocol: Efficacy and Safety of Radioembolization (REM) as an Early Modality (EM) Therapy for Metastatic Breast Cancer (BR) to the Liver with Y90 (REMEMBR Y90)Richard Wu, Keerthi Gogineni, Jane Meisel, et al.
Clinical Breast Cancer|March 7, 2020
A Roundtable Discussion of the Breast Cancer Therapy Expert Group (BCTEG): Clinical Developments and Practice Guidance on Human Epidermal Growth Factor Receptor 2 (HER2)-positive Breast CancerReshma Mahtani, Frankie-Ann Holmes, Sunil Badve, et al.
Journal of the Academy of Nutrition and Dietetics|January 13, 2015
¡Cocinar Para Su Salud!: Randomized Controlled Trial of a Culturally Based Dietary Intervention among Hispanic Breast Cancer SurvivorsHeather Greenlee, Ann Ogden Gaffney, A Corina Aycinena, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 16, 2021
Changes in Diffuse Optical Tomography Images During Early Stages of Neoadjuvant Chemotherapy Correlate with Tumor Response in Different Breast Cancer SubtypesMirella L Altoe, Kevin Kalinsky, Alessandro Marone, et al.
NPJ Breast Cancer|November 13, 2025
Evolving incidence patterns for locally advanced operable breast cancer by receptor status: SEER 2010-2021Alexandra Thomas, Anthony Rhoads, Erica L Mayer, et al.
Breast Cancer Research : BCR|February 1, 2021
Effects of neoadjuvant chemotherapy on the contralateral non-tumor-bearing breast assessed by diffuse optical tomographyMirella L Altoe, Kevin Kalinsky, Alessandro Marone, et al.
Cancer Investigation|September 26, 2014
Increased expression of tumor proliferation genes in Hispanic women with early-stage breast cancerKevin Kalinsky, Emerson A Lim, Eleni Andreopoulou, et al.
Breast Cancer Research and Treatment|June 13, 2024
Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practiceManali A Bhave, Julia C F Quintanilha, Hanna Tukachinsky, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 7, 2025
Clinical and Genomic Factors Associated with Elacestrant Outcomes in ESR1-Mutant Metastatic Breast CancerMaxwell R Lloyd, Caroline M Weipert, Azka Ali, et al.
Pageof 16